Vesalius Biocapital, a life sciences venture capital investor, has closed its fourth fund, Vesalius Biocapital IV, securing over €95 million of commitments.
The company plans to invest in first and best-in-class European life science companies in drug development and digital health. The goal is to build a portfolio of 10-15 companies, providing capital and the Vesalius team’s experience and expertise to support their development.
The fund has attracted blue chip investors including the European Investment Fund (EIF).
Now in its sixteenth year, Vesalius Biocapital has a successful track record of backing highly innovative companies and has raised over €270 million for its three previous funds.
It has completed over 30 investments with lead or co-lead positions and achieved numerous exits through trade sales and IPOs. These include: Forendo, acquired by Organon; Sword Health sold to a group of private equity investors; Apitope acquired by Chinese company Worg Pharma; and Ogeda acquired by Astellas Pharma.
Commenting on the first close, Stéphane Verdood, Managing Partner at Vesalius Biocapital IV, said: “This is an exciting time in healthcare; the industry is at a key inflection point between science, technology and medicine, and our investors support our strategy to invest in companies developing innovative first in class products and technologies.”
Vesalius Biocapital IV is targeting €150M and will accept new investors on a ‘rolling closing’ basis until the final closing in 2024.
